REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor.
"As we move into the next phase of Soleno's growth, we are delighted to welcome seasoned biopharmaceutical leaders Meredith, Dairine and Lauren as part of our leadership team as well as Shamim and Jim as key advisors," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. "Together, their wealth of industry knowledge and proven track records will significantly strengthen our capabilities in both the U.S. and Europe as we build towards becoming a commercial-stage company. We look forward to leveraging their collective expertise as we advance DCCR toward NDA and MAA filings and potential approval in Prader-Willi Syndrome."
Meredith Manning, M.B.A. brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices. Her expertise spans U.S. and global commercialization, brand building, and go-to-market strategies for products at all lifecycle stages, with significant experience in rare diseases. Prior to joining Soleno, she served as President of the Americas and a member of the U.S. Board of Directors at PharmaEssentia, where she led the U.S. regulatory approval and commercial launch of PharmaEssentia's first product, BESREMi®. Prior to PharmaEssentia, Ms. Manning served as the Chief Commercial Officer at resTORbio and as a vice president of marketing for a seven-brand hemophilia portfolio at Baxter BioScience (now Takeda). She previously held senior marketing and field leader roles at Vertex and Pfizer. Ms. Manning holds an M.B.A. from the University of Chicago Booth School of business and a B.A. in political science from Colorado College.
Dairine Dempsey, Ph.D., brings over 20 years of experience in the pharmaceutical, biologic, and device industries. She has been a consultant to Soleno since 2019. Prior to consulting, she founded and led the start-up phase of Open Orphan, a company specializing in orphan drugs. Prior to Open Orphan, she served as Global Vice President, Strategic Regulatory Affairs at ICON, where she navigated and resolved significant regulatory and compliance ...